Bristol Myers (BMY) AI Stock Analysis

• Market Cap: $103.18B
• Dividend Yield: 4.82%
• Average Volume (3M): 13.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: 4.62%
• EPS Growth: N/A
• Country: US
• Employees: 34,100
• Sector: Healthcare
• Sector Strength: 57
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.67
• Shares Outstanding: 2,034,763,200
• 10 Day Avg. Volume: 15,231,899
• 30 Day Avg. Volume: 13,522,541
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.57
• Price to Cash Flow (P/CF): 7.00
• P/FCF Ratio: 7.60
• Enterprise Value/Market Cap: 1.51
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 4.53
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $56.06
• Price Target Upside: 10.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 21

Bristol-Myers Squibb's overall stock score reflects strong financial performance, particularly in cash flow generation and gross profitability. The recent earnings call provided positive revenue and EPS guidance, supporting a strong outlook. However, technical indicators show bearish momentum, and some regulatory and trial challenges persist. The balanced valuation and attractive dividend yield provide additional support.

Positive Factors

Financial Performance

Q1 revenues beat expectations, driven mostly by established brands like Eliquis, Opdivo, and Revlimid.

Growth Strategy

BMY is prioritizing external business development, which could add new growth drivers.

Product Development

Camzyos could benefit from a recently updated label that has reduced the frequency of echo monitoring for patients.

Negative Factors

Clinical Trials

The failures of two clinical trials—Camzyos in nHCM and Cobenfy in adjunctive schizophrenia—have contributed to the decline in BMY shares.

Earnings Outlook

Several years of down earnings are expected due to generic pressures, creating a challenging intermediate-term growth profile.

Market Performance

Despite positive earnings, shares underperformed compared to big biopharma peers.

Bristol Myers Business Overview & Revenue Model

Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

How the Company Makes Money

Bristol-Myers Squibb makes money primarily through the sale of prescription medications. The company's revenue model is based on the development and commercialization of proprietary drugs that address unmet medical needs. Key revenue streams include sales from leading drugs such as Opdivo, a cancer immunotherapy; Eliquis, an anticoagulant; and Revlimid, used in treating multiple myeloma. BMY also engages in strategic partnerships and collaborations with other pharmaceutical companies and research institutions to enhance its drug pipeline and expand its market reach. Additionally, the company invests in research and development to continuously innovate and bring new therapies to market, which contributes to its long-term revenue growth.

Bristol Myers Financial Statement Overview

Summary

Bristol-Myers Squibb demonstrates resilient financial performance with strengths in cash flow generation and gross profitability. However, net income variability and increased leverage pose potential risks. Continued focus on stabilizing earnings and managing liabilities will be crucial for sustained financial health.

Income Statement

The income statement reveals a stable performance with gross profit margins consistently strong around 70%. However, the net profit margin has fluctuated significantly, with a notable loss in 2024. Revenue growth has been stable, with a slight decline in recent periods. The EBIT and EBITDA margins are solid for the TTM, reflecting efficient cost management despite earlier fluctuations.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. The equity ratio has decreased over time, suggesting an increase in liabilities relative to assets. Return on equity has varied, impacted by fluctuating net income, with a recent improvement in profitability contributing positively.

Cash Flow

Cash flow analysis is favorable, with strong and improving free cash flow, highlighting efficient cash generation. The operating cash flow to net income ratio indicates robust cash conversion efficiency, although historical net income volatility presents some risk. Free cash flow growth is positive, supporting a strong cash position.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
48.30B	45.01B	46.16B	46.38B	42.52B
	Gross Profit
34.33B	34.31B	36.02B	36.45B	30.75B
	EBIT
5.89B	17.24B	10.33B	10.16B	5.13B
	EBITDA
3.22B	19.42B	19.23B	20.19B	5.04B
	Net Income Common Stockholders
-8.95B	8.03B	6.33B	6.99B	-8.99B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.86B	12.28B	9.12B	13.98B	14.55B
	Total Assets
92.60B	95.16B	96.82B	109.31B	118.48B
	Total Debt
51.20B	41.46B	40.72B	45.60B	51.67B
	Net Debt
40.85B	30.00B	31.59B	31.62B	37.13B
	Total Liabilities
76.22B	65.67B	65.70B	73.31B	80.60B
	Stockholders Equity
16.34B	29.43B	31.06B	35.95B	37.82B
Cash Flow		Free Cash Flow
13.94B	12.65B	11.95B	15.23B	13.30B
	Operating Cash Flow
15.19B	13.86B	13.07B	16.21B	14.05B
	Investing Cash Flow
-21.35B	-2.29B	-1.06B	-538.00M	-10.86B
	Financing Cash Flow
5.13B	-9.42B	-16.96B	-16.22B	-1.15B

Bristol Myers Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 50.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMY, the sentiment is Negative. The current price of 50.57 is above the 20-day moving average (MA) of 50.52, below the 50-day MA of 55.62, and below the 200-day MA of 53.08, indicating a neutral trend. The MACD of -1.86 indicates Negative momentum. The RSI at 43.48 is Neutral, neither overbought nor oversold. The STOCH value of 90.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMY.

Bristol Myers Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	76 Outperform	$209.31B	12.11	40.81%	3.80%	4.26%	―
SNY	71 Outperform	$125.03B	21.43	7.34%	2.67%	-4.57%	2.96%
GILD	68 Neutral	$129.25B	21.82	32.58%	2.99%	4.71%	1144.01%
PFE	66 Neutral	$137.25B	17.54	9.05%	6.98%	13.38%	―
GSK	65 Neutral	$77.74B	24.21	22.26%	3.92%	4.17%	-29.96%
BMY	63 Neutral	$103.18B	―	31.99%	4.82%	4.62%	―
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%

Bristol Myers Corporate Events

Bristol-Myers Squibb Q1 2025 Financial Results Announced

On April 24, 2025, Bristol Myers Squibb announced its financial results for the first quarter of 2025, reporting total revenues of $11.2 billion, a decrease of 6% compared to the previous year. Despite the decline in total revenues, the company’s Growth Portfolio showed significant progress with a 16% increase in revenues, driven by strong performances from products like Opdivo, Breyanzi, Reblozyl, and Camzyos. The company raised its 2025 revenue guidance to a range of $45.8 billion to $46.8 billion, reflecting confidence in its strategic initiatives and pipeline progress.

Spark’s Take on BMY Stock

According to Spark, TipRanks’ AI Analyst, BMY is a Neutral.

Bristol-Myers Squibb’s overall score reflects strong financial performance in terms of revenue growth and cash flow, but is negatively impacted by significant net losses and high leverage. Technical indicators suggest a bearish trend, while the valuation is pressured by a negative P/E ratio despite a strong dividend yield. The positive sentiment from the earnings call, with optimistic guidance and strategic initiatives, helps counterbalance some risks.

To see Spark’s full report on BMY stock, click here.

Bristol-Myers Squibb Reports Strong Q4 2024 Financial Results

On February 6, 2025, Bristol-Myers Squibb announced its financial results for the fourth quarter and full year of 2024, highlighting a revenue increase to $12.3 billion for the fourth quarter, driven by its Growth Portfolio and increased demand for Eliquis. The company also reported achieving significant clinical and regulatory milestones, including the U.S. approval of Opdivo Qvantig and the launch of Cobenfy for schizophrenia treatment, positioning these developments as new growth drivers. The company aims for additional cost savings through its strategic productivity initiative, projecting $2 billion in savings by 2027.